Synlett 2024; 35(19): 2155-2173
DOI: 10.1055/a-2222-1667
account
Isotopic Labeling

Method Development and Syntheses Examples of Isotopically Labeled Compounds to Foster Operational Excellence in Pharma Industry

Anna Sib
,
Volker Derdau


The manuscript is dedicated to Prof. Laschat at the occasion of her 60th birthday – thanks Sabine.

Abstract

The different topics and synthetic approaches in an isotope chemistry laboratory of a pharma company are described. Besides the challenges in the synthesis of long-lived isotopes such as 3H or 14C, short-lived isotopes such as 68Ga and stable isotopes such as 15N, 13C or 2H approaches for the isotopic labeling are also demonstrated. Furthermore, method development with emphasis on collaborations with academic groups to tackle the future challenges are discussed.

1 Introduction

2 Isotopic Labeling with Hydrogen Isotopes Deuterium (2H, D) and Tritium (3H, T)

2.1 Deuterium Labeling for MS Standards

2.1.1 Labeled Nitrosamines – The Hunt to Quantify Hazardous Impurities

2.1.2 Deuterated Drugs, an Approach To Improve Existing Drugs or To Find Opportunities in Drug Discovery

2.2 Tritium-Labeling Methods – The Fast Approach to Radioactively Labeled Compounds

2.2.1 Hydrogen Isotope Exchange by Iridium Catalysis

2.2.2 Ruthenium-Catalyzed HIE

2.2.3 Nanoparticles as Catalysts in HIE

2.2.4 Photoredox-Catalyzed HIE

2.2.5 HIE via Classical Radical Mechanism

2.2.6 Beyond HIE – Halogen–Tritium Exchange

3 Challenges in 14C-Synthesis Projects

4 Short-Lived Isotopes – The Need for Speed

5 Beyond Isotope Science – Late-Stage Functionalization

5.1 Examples of Late-Stage Functionalization for Peptides

5.2 Examples of Catalyst-Controlled Late-Stage Functionalization

6 Conclusion



Publication History

Received: 31 October 2023

Accepted after revision: 04 December 2023

Accepted Manuscript online:
04 December 2023

Article published online:
17 January 2024

© 2023. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany